Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Mar;3(2):362-8.
doi: 10.2215/CJN.03450807. Epub 2008 Jan 30.

Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes

Susumu Ogawa  1 , Takefumi Mori, Kazuhiro Nako, Tsuneo Ishizuka, Sadayoshi Ito
Affiliations
Randomized Controlled Trial

Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes

Susumu Ogawa et al. Clin J Am Soc Nephrol. 2008 Mar.

Abstract

Background and objectives: Sarpogrelate has been shown to reduce albuminuria in diabetic nephropathy. For examination of whether this is based on the same mechanisms as angiotensin II receptor blockers or thiazolidinedione, effects of sarpogrelate on atherosclerotic inflammatory molecules and their relations to albuminuria in patients who had diabetes and had already been treated with angiotensin II receptor blockers and with or without thiazolidinedione were examined.

Design, setting, participants, & measurements: Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20). Plasma monocyte chemoattractant protein-1 and urinary albumin-to-creatinine ratio and monocyte chemoattractant protein-1 were measured at baseline and 16 wk after administration.

Results: Only the sarpogrelate group showed increases in plasma adiponectin and decreases in both plasma and urinary monocyte chemoattractant protein-1 and albumin-to-creatinine ratio levels. Moreover, percentage change of monocyte chemoattractant protein-1 level correlated positively to that of albumin-to-creatinine ratio. Even when the sarpogrelate group was further divided into two groups with (n = 9) or without thiazolidinedione (n = 11), changes in monocyte chemoattractant protein-1 or albumin-to-creatinine ratio did not differ.

Conclusions: Sarpogrelate can reduce albuminuria and plasma and urinary monocyte chemoattractant protein-1 levels while increasing plasma adiponectin in diabetic nephropathy. These effects seem to be mediated via mechanisms that are different from those of angiotensin II receptor blocker or thiazolidinedione.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Correlation of percentage change of adiponectin, monocyte chemoattractant proein-1 (MCP-1), and albumin-to-creatinine ratio (ACR) in the sarpogrelate administration group. The percentage change of adiponectin correlated negatively to that of plasma MCP-1 levels (A), and the percentage changes of plasma and urinary MCP-1 correlated positively to that of change of ACR (B and C); however, the percentage change of adiponectin did not correlate with that of change of ACR (D).
Figure 2.
Figure 2.
Correlation of change of plasma, urinary MCP-1, and ACR in the whole study population. Neither percentage change of plasma MCP-1 nor percentage change of urinary MCP-1 correlated to percentage change of ACR.
See this image and copyright information in PMC

References

    1. Doggrell SA: Sarpogrelate: Cardiovascular and renal clinical potential. Expert Opin Investig Drugs 13: 865–874, 2004 - PubMed
    1. Ogawa S, Takeuchi K, Sugimura K, Sato C, Fukuda M, Lee R, Ito S, Sato T: The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients. Clin Exp Pharmacol Physiol 26: 461–464, 1999 - PubMed
    1. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Snapinn SM, Wan Y, Lyle PA: Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 29: 595–600, 2006 - PubMed
    1. Grewal JS, Mukhin YV, Garnovskaya MN, Raymond JR, Greene EL: Serotonin %-HT2A receptor induces TGF-beta1 expression in mesangial cells via ERK: Proliferative and fibrotic signals. Am J Physiol 276: F922–F930, 1999 - PubMed
    1. Kasho M, Sakai M, Sasahara T, Anami Y, Matsumura T, Takemura T, Matsuda H, Kobori S, Shichiri M: Serotonin enhances the production of type IV collagen by human mesangial cells. Kidney Int 54: 1083–1092, 1998 - PubMed

Publication types

MeSH terms